Why Agenus Stock Is Marching Higher Today

·2 min read
Why Agenus Stock Is Marching Higher Today

Shares of the small-cap immunotherapy company Agenus (NASDAQ: AGEN) were up by a healthy 9.98% as of 11:08 a.m. EDT Thursday morning. The biotech's stock is rising today in response to the Food and Drug Administration's acceptance of the company's Biologics License Application (BLA) for balstilimab. Balstilimab is an anti-PD-1 antibody indicated for the treatment of recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting